Summary

Part 1 of A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus-1 Infected Participants (MK-1439-007) [NCT01632345] examined the safety, tolerability, pharmacokinetics, and efficacy of 4 doses of doravirine (25, 50, 100, and 200 mg once daily) versus efavirenz, both taken with emtricitabine-tenofovir. The Part 1 efficacy and safety results demonstrated that all 4 doses of doravirine had potent antiretroviral activity and fewer drug-related adverse events than efavirenz [Morales-Ramirez et al. CROI 2014].